PMID- 17292562
OWN - NLM
STAT- MEDLINE
DCOM- 20070504
LR  - 20191210
IS  - 0344-0338 (Print)
IS  - 0344-0338 (Linking)
VI  - 203
IP  - 3
DP  - 2007
TI  - Tissue microarray technology in breast cancer HER2 diagnostics.
PG  - 169-77
AB  - Tissue microarrays (TMAs) as current medical research tools significantly lower 
      the costs of immunohistochemical examinations (IHC) and fluorescence in situ 
      hybridization (FISH) while enabling high levels of standardization and 
      reliability. Taking HER2 testing of breast cancer into consideration, we assessed 
      the routine applicability of TMAs. A hundred and seventy-four consecutive samples 
      of invasive breast cancer cases were selected. TMAs were constructed in order to 
      conduct double HER2 immunohistochemical analysis and FISH abreast using the 
      conventional slide by slide method. Comparing the immunohistochemical data 
      obtained from TMAs with the routinely processed large sections, we found a 
      94.5%/92.7%, 85.7%/88.9% and 91.2%/90% concordance at immunohistochemically 
      HER2-negative, HER2 2+ and 3+ cases using the CB11/HercepTest, respectively. FISH 
      performed on TMAs helped to determine Herceptin therapy suitability in all cases, 
      and when discordance was found, we controlled FISH on "large sections". Being 
      able to conduct FISH examinations at a reasonable price with or without prior 
      immunohistochemical analysis, departments confronted with a certain frequency of 
      breast cancer cases might extensively use the type of TMAs applied in our study. 
      This is a relieve not only with regard to diagnostic work using microarrays, but 
      this also allows to take new directions in research by shedding light on certain 
      unusual cases.
FAU - Egervari, Kristof
AU  - Egervari K
AD  - Department Pathology, Medical and Health Science Center, University of Debrecen 
      Nagyerdei krt, 98 H-4012 Debrecen, Hungary.
FAU - Szollosi, Zoltan
AU  - Szollosi Z
FAU - Nemes, Zoltan
AU  - Nemes Z
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
DEP - 20070209
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA Probes)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Breast Neoplasms/chemistry/*diagnosis/drug therapy/genetics/pathology
MH  - DNA Probes
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/instrumentation
MH  - In Situ Hybridization, Fluorescence/instrumentation
MH  - Molecular Diagnostic Techniques/*instrumentation/standards
MH  - Patient Selection
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/*analysis/genetics/immunology
MH  - Reproducibility of Results
MH  - Tissue Array Analysis/*instrumentation/standards
MH  - Trastuzumab
EDAT- 2007/02/13 09:00
MHDA- 2007/05/05 09:00
CRDT- 2007/02/13 09:00
PHST- 2006/07/04 00:00 [received]
PHST- 2006/11/20 00:00 [revised]
PHST- 2006/12/07 00:00 [accepted]
PHST- 2007/02/13 09:00 [pubmed]
PHST- 2007/05/05 09:00 [medline]
PHST- 2007/02/13 09:00 [entrez]
AID - S0344-0338(07)00003-9 [pii]
AID - 10.1016/j.prp.2006.12.004 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2007;203(3):169-77. doi: 10.1016/j.prp.2006.12.004. Epub 2007 
      Feb 9.